Skip to content

US · MGX · BIOTECHNOLOGY

Metagenomi, Inc. Common Stock (MGX) intrinsic value and stock valuation

$0.57as of 2026-11-21 · Mkt cap 45.74M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Metagenomi, Inc. Common Stock DCF and intrinsic value

InvestorsCraft values MGX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MGX’s statements →

Metagenomi, Inc. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Emeryville, CA 94608 metagenomi.co

How the business is doing

Fiscal 2021–2025, USD

Revenue
$25.2M
20212025
Net income
-$-87.87M
20212025
Free cash flow
-$-89.47M
20212025
Total equity
$158.6M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$25.2M$52.3M$44.8M$17.2M$240K
Operating income-$-96.01M-$-88.9M-$-78.49M-$-44.64M-$-23.95M
Net income-$-87.87M-$-78.06M-$-68.25M-$-43.59M-$-21.44M
EPSd-$-2.36M-$-2.09M-$-1.82M-$-1.16M-$-3.62M
Operating cash flow-$-88.89M-$-109.07M-$-91.41M$29.7M$24.3M
Capital expenditure-$-570K-$-3.11M-$-9.81M-$-13.98M-$-2.9M
Free cash flow-$-89.47M-$-112.19M-$-101.22M$15.8M$21.4M
Total assets$221.1M$324.6M$364.8M$414.5M$142M
Total debt$40.7M$45.8M$48.2M$18.6M$48.9M
Net debt-$-1.06M$18.4M-$-92.37M-$-165.87M$9.63M
Total equity$158.6M$234.9M$215.2M-$-74.43M-$-32.54M
Cash and short-term investments$160.8M$248.3M$271.2M$362.1M$108.2M
Income statement
20252024202320222021
Revenue$25.2M$52.3M$44.8M$17.2M$240K
Cost of revenue$5.32M$0.00$94.4M$1.73M$390K
Gross profit$19.9M$52.3M-$-49.65M$15.5M-$-140K
Research and development expenses$94.4M$109.2M$94.4M$43.1M$14.5M
Selling, general and administrative expenses$26.8M$32M$28.8M$18.7M$9.71M
Other expenses-$-5.32M$0.00-$-94.4M-$-1.73M-$-390K
Operating expenses$115.9M$141.2M$28.8M$60.1M$23.8M
Cost and expenses$121.2M$141.2M$123.3M$61.8M$24.2M
Interest income$9.47M$14.7M$15.5M$3.42M$40K
Interest expense$0.00$0.00$0.00$100K$300K
Depreciation and amortization$5.32M$5.41M$4.21M$1.73M$390K
Ebitda-$-82.61M-$-78.16M-$-56.02M-$-39.19M-$-20.75M
Operating income-$-96.01M-$-88.9M-$-78.49M-$-44.64M-$-23.95M
Total other income/expenses, net$8.09M$5.33M$18.3M$3.62M$2.5M
Income before tax-$-87.93M-$-83.57M-$-60.23M-$-41.02M-$-21.44M
Income tax expense-$-60K-$-5.51M$8.03M$2.57M$0.00
Net income-$-87.87M-$-78.06M-$-68.25M-$-43.59M-$-21.44M
Weighted average shares outstanding$37.3M$37.4M$37.5M$37.5M$5.93M
Weighted average diluted shares outstanding$37.3M$37.4M$37.5M$37.5M$5.93M
Balance sheet
20252024202320222021
Cash and short-term investments$160.8M$248.3M$271.2M$362.1M$108.2M
Net receivables$300K$1.26M$2.45M$1.27M$490K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$165.5M$258M$278.3M$366.9M$108.9M
Property, plant and equipment, net$47.4M$57.7M$65.2M$33.3M$22.1M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$2.15M$3.45M$15.9M$7.81M$6.42M
Total non-current assets$55.6M$66.6M$86.6M$47.6M$33.1M
Total assets$221.1M$324.6M$364.8M$414.5M$142M
Accounts payable$1.49M$530K$1.79M$2.01M$1.35M
Short-term debt$6.03M$5.59M$6.85M$1.51M$690K
Deferred revenue$8.7M$22.8M$48.9M$33.9M$16M
Total current liabilities$22.9M$37.3M$68.9M$48.5M$25.2M
Long-term debt$34.6M$40.2M$44.8M$17.1M$48.2M
Deferred revenue, non-current$2.99M$10.2M$30.9M$76.2M$23.7M
Total non-current liabilities$39.6M$52.4M$80.8M$440.4M$149.4M
Capital lease obligations$40.7M$45.8M$48.2M$18.6M$18.7M
Total liabilities$62.5M$89.7M$149.7M$488.9M$174.5M
Common stock$0.00$0.00$30K$2.54M$570K
Retained earnings-$-310.87M-$-223M-$-144.94M-$-76.69M-$-33.1M
Accumulated other comprehensive income (loss)$260K$710K$9.33M-$-270K-$-20K
Total equity$158.6M$234.9M$215.2M-$-74.43M-$-32.54M
Total investments$121.2M$224.4M$146.5M$185.5M$75.3M
Total debt$40.7M$45.8M$48.2M$18.6M$48.9M
Net debt-$-1.06M$18.4M-$-92.37M-$-165.87M$9.63M
Cash flow statement
20252024202320222021
Net income-$-87.87M-$-78.06M-$-68.25M-$-43.59M-$-21.44M
Depreciation and amortization$5.32M$5.41M$4.21M$1.73M$390K
Stock-based compensation$11.9M$16.2M$6.92M$1.96M$380K
Change in working capital-$-22.09M-$-59.67M-$-26.43M$69.5M$46.3M
Accounts receivable$950K$1.19M-$-1.18M-$-1.27M$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.05M-$-1.11M-$-80K$720K$690K
Net cash provided by operating activities-$-88.89M-$-109.07M-$-91.41M$29.7M$24.3M
Investments in property, plant and equipment-$-570K-$-3.11M-$-9.81M-$-13.98M-$-2.9M
Acquisitions, net$40K$0.00$0.00$0.00$0.00
Net cash used for investing activities$103.5M-$-88.16M$45.7M-$-122.2M-$-74.32M
Common stock issued$200K$84M$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-360K$84M$1.01M$239.6M$39.9M
Net change in cash$14.3M-$-113.22M-$-44.66M$147.1M-$-10.14M
Cash at end of period$46.9M$32.6M$145.9M$190.5M$43.4M
Operating cash flow-$-88.89M-$-109.07M-$-91.41M$29.7M$24.3M
Capital expenditure-$-570K-$-3.11M-$-9.81M-$-13.98M-$-2.9M
Free cash flow-$-89.47M-$-112.19M-$-101.22M$15.8M$21.4M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Metagenomi, Inc. Common Stock

        Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.

        CEO
        Jian Irish
        Employees
        119
        Beta
        0.70

        Explore

        Frequently asked questions

        What is the intrinsic value of Metagenomi, Inc. Common Stock (MGX)?

        InvestorsCraft does not currently publish an intrinsic value for MGX. How the IC value is calculated.

        Is MGX undervalued?

        InvestorsCraft does not publish an undervaluation signal for MGX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.